Universität zu Köln

Wolber, P., Mayer, M., Nachtsheim, L., Prinz, J., Klussmann, J. P., Quaas, A. and Arolt, C. (2022). Expression of Mucins in Different Entities of Salivary Gland Cancer: Highest Expression of Mucin-1 in Salivary Duct Carcinoma Mucin-1-highest expression in Salivary Duct Carcinoma. Head Neck Pathol., 16 (3). S. 792 - 802. NEW YORK: SPRINGER. ISSN 1936-0568

Full text not available from this repository.

Abstract

Therapeutic options for advanced salivary gland cancer (SGC) are rare. Therefore, it was the aim of this study to investigate the extent and intensity of Mucin-1 (MUC1), Mucin-16 (MUC16), and Mucin-5AC (MUC5AC) as potential molecular targets using immunohistochemistry. The medical records of all patients who underwent primary surgery for salivary gland cancer with curative intent in a tertiary referral center between 1990 and 2018 were reviewed. Immunohistochemical staining for MUC1, MUC16, and MUC5AC was performed for all patients with sufficient formalin-fixed paraffin-embedded material, and a semi-quantitative combined score derived from the H-score for the cytoplasmatic, the membranous and the apical membrane was built for the most common entities of SGC. 107 patients with malignancies of the parotid (89.7%) and the submandibular gland (10.3%) were included. The most common entities were mucoepidermoid carcinoma (MuEp; n = 23), adenoid cystic carcinoma (AdCy; n = 22), and salivary duct carcinoma (SaDu; n = 21). The highest mean MUC1 combined score was found in SaDu with 223.6 (+/- 91.7). The highest mean MUC16 combined score was found in MuEp with 177.0 (+/- 110.0). The mean MUC5AC score was low across all entities. A higher MUC1 combined score was significantly associated with male gender (p = 0.03), lymph node metastasis (p < 0.01), lymphovascular invasion (p = 0.045), and extracapsular extension (p = 0.03). SaDu patients with MUC16 expression showed a significantly worse 5-year progression-free survival than those without MUC16 expression (p = 0.02). This is the first study to give a comprehensive overview of the expression of MUC1, MUC16, and MUC5AC in SGC. Since advanced SGCs lack therapeutic options in many cases, these results warrant in vitro research on therapeutic targets against MUC1 in SaDu cell lines and xenograft models.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wolber, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mayer, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Nachtsheim, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Prinz, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Klussmann, J. P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Quaas, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Arolt, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-660789
DOI:	10.1007/s12105-022-01448-3
Journal or Publication Title:	Head Neck Pathol.
Volume:	16
Number:	3
Page Range:	S. 792 - 802
Date:	2022
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1936-0568
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MUC1; IMMUNOTHERAPY; ONCOPROTEIN; MANAGEMENT; SURVIVAL; PLACEBO; PROTEIN; MUC5AC; TARGET; HEAD Multiple languages Pathology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66078